COVİD-19 AŞISI SONRASI GELİŞEN PERİKARDİYAL EFÜZYON VE KARDİYAK TAMPONAD: NADİR BİR OLGU SUNUMU

Abstract

Bilinen kronik hastalık öyküsü olmayan 44 yaşında kadın hasta, covid-19 aşısı (Pfizer-Biontech) sonrası taşikardi ve nefes darlığı şikayetiyle acil servise başvurdu. Kardiyolojiye konsülte edilen hastanın tansiyonu: 80/40 mmHg. Ekokardiyografi (EKO): Ejeksiyon Fraksiyonu %65, en geniş noktasında kalbi çepeçevre saran ve sağ kalp boşluklarını diyastolde kollabe ederek tamponad kliniğini oluşturan 5 cm perikardiyal efüzyon (PE) mevcuttu. Hastaya acil perikardiyosentez uygulandı. Hastanın perikardiyal sıvı içeriği seröz idi. Perikardiyosentez sonrası klinik durumu stabilize olan hasta koroner yoğun bakım ünitesinde takip edildi. Takiplerinde kontrol ekoda perikardiyal efüzyon izlenmedi. Hastanın Covid-19 a yönelik yapılan PCR sonuçları negatifti. Hasta kardiyoloji poliklinik kontrolü ile taburcu edildi.

Keywords

• Covid-19
• Perikardiyal efüzyon
• Aşı
• Kardiyak tamponad.

PERICARDIAL EFFUSION AND CARDIAC TAMPONADE AFTER COVID-19 VACCINE: A RARE CASE REPORT

Abstract

A 44-year-old female patient with no known history of chronic disease was admitted to the emergency room with tachycardia and shortness of breath after covid-19 vaccine (Pfizer Biontech). The blood pressure of the patient who was consulted to cardiology: 80/40 mmHg. Echocardiography (ECHO): Ejection Fraction was 65%, pericardial effusion (PE) was present at its widest point, 5 cm encircling the heart, collapsing the right heart cavities in diastole, forming the clinic of tamponade. Emergency pericardiocentesis was applied to the patient. Pericardial fluid content of the patient was serous. The patient, whose clinical stability was stabilized after pericardiocentesis, was followed in the coronary intensive care unit. No pericardial effusion was observed in the control echo duringfollow-up. Thepatient's PCR results were negative. The patient was discharged with cardiology outpatient control.

Keywords

• Covid-19
• Pericardial effusion
• Vaccine
• Cardiac tamponade.

References

1. World Health Organization. Geneva (Switzerland): Novel coronavirus (2019-nCoV), situation report-1, 21 January 2020 [Internet] [cited 2020 Mar 2]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf
2. Farina A, Uccello G, Spreafico M et al. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J InternMed 2020;76:100–01.
3. Dabbagh MF, Aurora L, D’Souza P et al. Cardiac tamponade secondary to COVID-19. JACC Case Rep 2020;2:1326–30.
4. Purohit R, Kanwal A, Pandit A. Acute myopericarditis with pericardial effusion and cardiac tamponade in a patient with COVID-19. Am J Case Rep 2020;21:e925554.
5. Asif T, Kassab K, Iskander F et al. Acute pericarditis and cardiac tamponade in a patient with COVID-19: a therapeutic challenge. Eur J Case RepInternMed 2020;7:001701.
6. Hua A, O’Gallagher K, Sado D et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. EurHeart J 2020;41:2130.
7. Fox K, Prokup JA, Butson K et. al: Acute effusive pericarditis: a late complication of COVID-19 . Cureus. 2020, 12:9074. 10.7759/cureus.9074.
8. Dong N, Cai J, Zhou Y et al. End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV. JACC Heart Fail 2020;8:515–17.

9. Jin Y, Yang H, Ji W et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12:372.
10. Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420.